To study the biological relevance of using bovine herpesvirus-1 (BHV-1) as a vector for expressing cytokines, a BHV-1 virus that expressed bovine interferon-γ (IFN-γ) was constructed. This recombinant virus (BHV-1/IFNγ) was then used to infect the natural host in a respiratory disease model. 
Introduction
Bovine herpesvirus-1 (BHV-1) is a member of the subfamily Alphaherpesvirinae, genus Varicellovirus. Current interest in BHV-1 vaccine development has focused on the use of subunit vaccines, gene-deleted viruses and killed and live virus vectors (van Drunen Littel-van den Hurk et al., 1993 ; . The deletion mutants are used both to attenuate the virus and to serve as marker vaccines to distinguish vaccinated animals from naturally infected animals. These gene-deleted viruses can also be used as vectors for genes encoding an array of putative protective antigens or immunomodulatory molecules. The production of cytokines at the site of virus replication could have significant immunomodulation potential that could assist the host in controlling virus replication, preventing latency and possibly preventing secondary bacterial infections. The construction of a recombinant BHV-1 vector containing interferon-γ (IFN-γ) made it possible to investigate this novel vaccine approach in a Author for correspondence : Philip Griebel. Fax j1 306 966 7478. e-mail griebelp!sask.usask.ca primary respiratory infection model and following the reactivation from a latent infection.
IFN-γ has numerous immunological regulatory functions that may be beneficial in modulating virus diseases in cattle. These include Fc receptor up-regulation, activation of macrophages and polymorphonuclear phagocytic functions, upregulation of major histocompatibility complex (MHC) class I and class II and inhibition of virus replication (Campos et al., 1989 ; Boehm et al., 1997) . The production of IFN-γ by lymphocytes following BHV-1 infection plays an important role in the activation of non-MHC-restricted cytotoxicity (Campos et al., 1989) . In addition, bovine IFN-γ (boIFN-γ) has been shown to up-regulate the expression of various immunespecific molecules, including MHC class II, Fc receptor and C3b receptor, and to influence a variety of effector functions (Bielefeldt Ohmann et al., 1987) .
The capacity of IFN-γ to modulate virus infections when expressed in a recombinant virus vector has been investigated with several different viruses. A vaccinia virus (VV) vector expressing IFN-γ was shown to attenuate a typically lethal virus infection in an immunodeficient mouse model (KohonenCorish et al., 1990 ; Giavedoni et al., 1992) . Recently, expression of recombinant IFN-γ by a simian immunodeficiency virus (SIV) vector resulted in significantly lower virus loads in the blood of rhesus macaque monkeys when compared to mutant vector controls (Giavedoni et al., 1997) .
A BHV-1 vector expressing boIFN-γ (BHV-1\IFNγ) could potentially have beneficial immunomodulating effects. In this study, we evaluated the stability and biological activity of recombinant BHV-1\IFNγ during a primary infection of its natural host and following the reactivation of a latent herpesvirus infection.
Methods
Virus and cells. The Cooper strain of BHV-1, obtained from the National Veterinary Services Laboratories (Ames, IA, USA), was used as the prototype virus. A glycoprotein C (gC)-negative mutant expressing the LacZ gene (BHV-1δgIII\LacZ) was previously produced and is designated gC − \LacZ + (Liang et al., 1992) . Field isolate of BHV-1 strain 108 was obtained from the Animal Diseases Research Institute (Alberta, Canada). All viruses were propagated in Madin-Darby bovine kidney (MDBK) cells that were obtained from the ATCC. Cells were maintained in minimum essential medium (MEM) supplemented with 10 % foetal bovine serum (FBS) (Gibco\BRL).
Construction and characterization of recombinant virus. To construct a transfer vector with the boIFN-γ coding sequence, the boIFN-γ gene was isolated from plasmid pTrpBoγCAAXPG (Ciba Geigy) by an EcoRI\SspI digest followed by treatment with Klenow fragment to repair the protruding end (Cerretti et al., 1986) . A BamH1 linker (dCCGG-ATCCG) was added for insertion into the BamH1 site of transfer vector pSD113SSBam (Raggo et al., 1996) , resulting in transfer plasmid pSD113SSIFNγ. DNA sequencing of the gC-boIFNγ junction confirmed the correct coding sequence. The cleaved product was predicted to retain the 143 aa sequence from the mature protein of boIFN-γ plus 6 aa from the gC fusion protein at the amino terminus (ARDPEFM*QFF … ) (Cerretti et al., 1986) .
Parental BHV-1δgIII\LacZ (Liang et al., 1992) viral DNA was purified according to methods previously described (Raggo et al., 1996) . To generate recombinant virus, MDBK cells were co-transfected with 1n5 µg pSD113SSIFNγ and 10 µg BHV-1δgIII\LacZ DNA by lipofection. Plasmid and viral DNA in 35 µl dH # O plus 40 µl lipofectin (Gibco\BRL) were added to MDBK cells. The next day, Opti-MEM (Gibco\BRL) supplemented with 2 % FBS was added and cells were incubated for another day. Cells were then washed twice with MEM, trypsinized and resuspended into a 96-well plate. Wells expressing cytopathology were harvested and screened for β-galactose production by a blue plaque assay (Liang et al., 1992) . Since the parental virus contained the LacZ gene, blue plaques identified non-recombinant viruses and white plaques revealed virus that had undergone a recombination event. Positive white plaques were plaque-purified for further analysis. Southern blot analysis was performed as previously described (Raggo et al., 1996) . To analyse virus growth kinetics, 6-well plates of confluent MDBK cells were infected at an m.o.i. of 5 as previously described (Raggo et al., 1996) .
Bioassay for IFN-γ activity. BoIFN-γ activity was determined by a standard vesicular stomatitis virus (VSV) plaque inhibition assay as previously described (Campos et al., 1989) . The dilution of supernatant at which 50 % of VSV plaques were inhibited was taken as one unit of boIFN-γ activity.
MHC class II up-regulation by IFN-γ. Alveolar macrophages were isolated from the lungs of 2-to 3-month-old calves by lung lavage.
Briefly, calves were euthanized and both lungs were removed. MEM (1 l) was then poured into the trachea and the lung lobes were gently massaged. The lungs were next inverted to collect the MEM solution that contained alveolar macrophages. This procedure was repeated three times. The collected medium was pooled and centrifuged at 1500 r.p.m. in a Beckman GH-3.7 rotor for 10 min. The cell pellet was re-suspended and washed twice with MEM before viable cells were counted. Alveolar macrophages were incubated in 6-well plates at 15i10' cells per well in MEM containing 5 % FBS.
To detect IFN-γ-induced MHC class II up-regulation, 3 ml of isolated alveolar macrophages (4i10' cells\ml) were incubated with 2 ml of supernatant from MDBK cells infected with either wild-type Cooper virus, gC − \LacZ + or BHV-1\IFNγ. Virus supernatant was centrifuged at 75 000 g for 2 h to remove active virus. Control wells were incubated with either 100 ng\ml of recombinant boIFN-γ or MEM. After a 24 h incubation, cells were collected from the wells by incubating adherent cells in PBS-BSA solution supplemented with 0n05 % EDTA for 10 min. Cells were washed once and cell suspensions were placed into a 96-well plate (5i10& cells per well) and co-incubated for 30 min with lineagespecific monoclonal antibodies (MAbs) ; BoLa class II, a nonpolymorphic determinant (clone TH14B, IgG2a isotype) ; and monocyte-macrophage marker (clone DH59B, IgG1 isotype) [Veterinary Medical Research and Development (VMRD), Pullman, WA, USA]. After two washes with PBS, cells were incubated for 30 min with fluorescein isothiocyanate-conjugated (FITC) goat anti-mouse IgG1 or phycoerythrin (PE)-conjugated goat anti-mouse immunoglobulin (Becton Dickinson), then washed twice and fixed with 2 % formaldehyde. Cells were stored in the dark at 4 mC until analysed. The intensity of fluorescence was evaluated using a FACScan (Becton Dickinson) and the Cell Quest program. Non-specific staining was determined by incubating cells with isotype-matched control MAbs and the FITC-and PE-conjugated secondary antibodies. To determine the percentage of positive staining, 5000 cells were analysed. For each sample forward-and side-scatter were used to restrict flow cytometric analyses to mononuclear cells.
Venous blood samples were collected in EDTA vacuum tubes (Becton Dickinson). Total and differential white blood cell counts were determined by Prairie Diagnostic Services (Saskatchewan, Canada).
For flow cytometric analysis, leukocytes were incubated with MAbs specific for the following bovine leukocyte surface markers : CD3 (clone MM1A), CD4 (ILA12), CD8 (clone CACT80C), IgM (clone PIG45A), Bcell (BAQ44A) and granulocytes\monocytes (DH59B). Leukocytes were also dual-labelled for the MHC class II molecule (TH14B) and CD4 (ILA12). Antibodies were obtained from VMRD. The IL12A (CD4) monoclonal antibody was a generous gift from J. Ellis (Western College of Veterinary Medicine, Saskatoon, Canada). Labelling by MAbs was evaluated using a FACScan (Becton Dickinson) and the Lysis II program.
Cattle challenge model. All animals were cared for under the guidelines provided by the Canadian Council on Animal Care (1993). BHV-1 sero-negative 6-month-old Holstein calves were randomly divided into three groups. At day 0, animals were intranasally challenged with 4i10( p.f.u.\ml of either wild-type Cooper strain, gC − \LacZ + mutant or recombinant BHV-1\IFNγ aerosol using a Devilbiss nebulizer model 65. Approximately 3i10) p.f.u. of virus was administered by aerosol during a 5 min period. Each experimental group was housed separately to prevent cross-infection by different virus strains. Animals were monitored daily for 10 days by a veterinarian who assessed clinical responses. Thirty-five days after the primary infection, animals were treated for 5 days with 0n1 mg\kg dexamethasone to reactivate latent virus infections (Homan & Easterday, 1983) . Clinical responses were monitored and nasal swabs were taken to detect virus shedding for 10 days after dexamethasone treatment.
CGGG
Recombinant BHV-1 expressing IFN-γ Recombinant BHV-1 expressing IFN-γ (B) For the bioassay for recombinant boIFN-γ activity, confluent monolayers of MDBK cells in 6-well plates were infected with either wildtype Cooper BHV-1 or recombinant BHV-1/IFNγ. At the times indicated, culture supernatant and cellular fractions were harvested. Samples were assayed for boIFN-γ activity using a standard VSV plaque inhibition assay. IFN-γ activity of 1 U equals a 50 % reduction in VSV plaques. Recombinant boIFN-γ protein was used as a standard (sp. act. 3i10 6 U/mg). (C) To establish virus growth kinetics, confluent MBDK cell monolayers were inoculated at an m.o.i. of 5. After 1 h, cells were washed three times and incubated with MEM supplemented with 10 % FBS. At various times p.i., medium was collected and the BHV-1 titre was assayed. The supernatant Clinical observation. Clinical examination included rectal temperatures, assessing depression and an examination for nasal lesions. A sick score was calculated by adding the scores for nasal lesions and depression, which were each ranked from normal (0) to severe (4). Nasal lesion scores were based on nasal discharge and mucosal hyperaemia. Depression score was based on appetite, awareness and activity.
Virus isolation and mucus collection. Samples to evaluate virus shedding were collected by inserting a cotton swab into the nasal cavity and rubbing the mucosa. The cotton swab was then placed into 1 ml MEM and stored at k70 mC until virus titre was determined. To collect nasal secretions, a cotton tampon was inserted into one nostril for 20 min and then placed into a 50 ml sterile syringe to extract the fluids.
ELISA. To detect BHV-1 antibody levels, Immunolon-II microtitre plates (Dynatech) were coated overnight with 0n05 µg per well of purified tgD protein (van Drunen Littel-van den Hurk et al., 1984) in 50 mM carbonate buffer (pH 9n6). Bound IgG was detected by adding a 1 : 10 000 dilution of phosphatase-conjugated goat anti-bovine IgG (Kirkegaard & Perry Laboratory). Plates were developed by the addition of substrate pnitrophenyl phosphate di(Tris) salt (Sigma) in 0n5 mM MgCl # (pH 9n8) with 1 % diethanolamine. A BioRad 3550 microplate reader was used to read plates at a wavelength of 405 nm (reference of 490 nm).
The gD-specific IgA was detected in a similar manner using a mouse anti-bovine IgA (clone M67) MAb at a 1 : 5000 dilution, followed by a biotinylated horse anti-mouse IgG at 1 : 5000 (Vector Laboratories) and a 1 : 1000 dilution of streptavidin-alkaline phosphatase (SAP) for 1 h (Gibco\BRL).
BoIFN-γ was detected with a capture ELISA. Immunolon II plates were coated with MAb (clone 2-2-1) diluted 1 : 1000 in 50 mM carbonate buffer (pH 9n6). Samples were serially diluted, added to the wells and incubated for 2 h at room temperature. After washing, rabbit anti-boIFN-γ polyclonal antisera (lot 92-131), diluted 1 : 2000, was added for 1 h. Biotinylated goat anti-rabbit IgG, diluted 1 : 1000, was used for developing with the SAP system. To calculate the concentration of IFN-γ in a test sample, recombinant boIFN-γ (Ciba Geigy) was used to generate a standard curve. The 36 h growth kinetics curve of culture supernatant from vector-produced IFN-γ was compared to the recombinant boIFN-γ standard curve and calculated to contain 512 U\ ml activity and a protein concentration of 182 ng\ml (sp. act. 2n8i10' U\mg).
BoIFN-γ enzyme-linked immunospot assay (ELISPOT). ELISPOT was used to determine the number of IFN-γ-secreting cells present in the blood. Blood mononuclear cells (PBMCs) were isolated by layering buffy coat cells over 60 % Percoll (Pharmacia). PBMCs were cultured in 24-well plates at a concentration of 6i10' cells per well in culture medium containing 5 % FBS, 2 mM glutamine, 50 mM 2-mercaptoethanol and 5 ng\ml dexamethasone in the presence or absence of 0n4 µg per well of purified gD protein. Dexamethasone was added to the culture medium to decrease the background frequency of non-specific IFN-γ-secreting cells. Nitrocellulose plates (Amicon) were coated with a MAb for boIFN-γ (clone 2-2-1) diluted 1 : 400 in 50 mM carbonate buffer (pH 9n6) at 37 mC. Following a 24 h culture, PBMCs were harvested and viable cells were plated at 1i10', 5i10& and 2n5i10& cells per well in the pre-coated 96-well nitrocellulose-based microtitre plates. After incubation for 8-16 h, the plates were washed twice with cold H # O and five times with PBS. To detect bound boIFN-γ, rabbit anti-boIFN-γ antisera (lot 92-131) was added at 1 : 100 dilution for 2 h at room was titred by plaque assay in 24-well plates. Cooper strain wild-type ; gC − , a gC-negative mutant ; BHV-1/IFNγ, gC-negative mutant expressing boIFN-γ. C. Raggo and others C. Raggo and others temperature. Plates were washed and incubated with a 1 : 2500 dilution of biotinylated rat anti-rabbit IgG (Zymed) for 2 h, followed by incubation with a 1 : 1000 dilution of SAP for 1 h. IFN-γ spots were developed with 5-bromo-4-chloro-3-indoyl phosphate Nitro Blue Tetrazolium substrate (Sigma). The number of gD-specific IFN-γ-secreting cells was determined by subtracting the number of spots in wells with PBMCs cultured in the absence of purified gD protein.
Statistical analysis. Statistical analysis was performed by the GraphPad PRISM program (GraphPad Software). Groups were compared by Student's t-test, analysis of variance or the Mann-Whitney rank-sum test as indicated in the figure legends.
Results
Recombinant BHV-1 was generated by co-transfection of MDBK cells with transfer plasmid pSD113SSIFNγ and purified DNA from BHV-1δgIII\LacZ (Liang et al., 1992) . Recombinant viruses were screened by blue plaque assay. White plaques were identified and plaque-purified twice. A purified progeny virus was designated BHV-1\IFNγ and was used for further characterization. To confirm the genomic rearrangement of the boIFN-γ gene in the gC region, Southern blot analysis was carried out using total cellular DNA from both wild-type virus and recombinant virus (Fig. 1 A) . The gC probe containing both 5h and 3h ends hybridized to a 3n0 kb fragment in the wildtype lane, whereas the lane containing recombinant BHV-1\IFNγ had two fragments of 1n5 kb and 0n7 kb. The insertion of boIFN-γ created a unique EcoRI site in front of the gC signal sequence, which resulted in two fragments. The boIFN-γ probe did not hybridize to wild-type DNA ; a 1n5 kb fragment was detected with BHV-1\IFNγ DNA.
BHV-1/IFNγ produces biologically active IFN-γ
To ascertain whether BHV-1\IFNγ-produced recombinant boIFN-γ protein had biological activity, the supernatant from cell cultures infected with BHV-1\IFNγ virus was tested in a standard anti-virus VSV assay. IFN-γ activity was detected as early as 6 h post-infection (p.i.) and this activity was detected throughout the sampling period (Fig. 1 B) . At 36 h p.i., the supernatant fraction contained the majority of antiviral activity (512 U\ml) while activity in the cellular fraction remained constant after 24 h p.i. (256 U\ml). Furthermore, the specific activity of the recombinant boIFN-γ produced by BHV-1\IFNγ was calculated to be 2n8i10' U\mg using a boIFN-γ capture ELISA. This specific activity is comparable to the E. coliproduced recombinant boIFN-γ standard of 3i10' U\mg (Ciba Geigy).
Expression of boIFN-γ does not alter in vitro virus growth
To assess the in vitro growth efficiency of the recombinant BHV-1\IFNγ, a growth kinetics experiment was performed. MDBK cells were infected with either wild-type Cooper, gC − \LacZ + or BHV-1\IFNγ virus. Both recombinant viruses exhibited similar growth kinetics with virus yields approximately 10-to 100-fold lower than wild-type virus (Fig. 1 C) . The maximal yield for recombinant gC-negative phenotype viruses was approximately 4i10( p.f.u.\ml while wild-type Cooper virus produced greater than 2i10) p.f.u.\ml. Therefore, the production of biologically active boIFN-γ did not alter the in vitro growth of recombinant BHV-1. The observation that recombinant boIFN-γ did not alter BHV-1 growth is consistent with previous reports that herpesviruses are generally resistant to the antiviral activity of interferons Bielefeldt Ohmann et al., 1984) .
Infection of cattle with BHV-1/IFNγ
Since in vitro growth curve studies of BHV-1\IFNγ showed no inhibitory effect on virus growth, three different groups of sero-negative calves were challenged with either BHV-1\IFNγ, gC-negative parental virus or wild-type BHV-1 virus. All calves responded to infection with an increased body temperature ( 39n5 mC). Elevated rectal temperatures began 2 days p.i. and peaked 4-5 days p.i. (Fig. 2 A) . Clinical scores were also elevated 2 days p.i. and peaked at days 4-6 p.i. for all groups. Clinical symptoms included increased nasal discharge, coughing, nasal mucosa hyperaemia and plaque formation in the nares of all animals. Overall, changes in body temperature and clinical score were similar in the three groups and paralleled what would be expected in the BHV-1 challenge CGGI Recombinant BHV-1 expressing IFN-γ Recombinant BHV-1 expressing IFN-γ Fig. 3 . IFN-γ concentration in nasal secretions. Samples were collected with nasal tampons every second day post-infection. BoIFN-γ concentrations were determined by ELISA. The detection limit for IFN-γ ELISA assay was 10 pg/ml. Samples with undetectable levels of IFN-γ are not included. An asterisk indicates animals that were sampled for IFN-γ levels at days 0, 12 and 14 but levels of IFN-γ were below the level of detection. Values for individual animals are shown with experimental groups indicated in the figure. model (Wyler et al., 1989 ; Yates, 1982) . Thus, the expression of boIFN-γ by BHV-1\IFNγ had no detectable effect on the clinical response to virus infection.
Virus was isolated in nasal swabs from all animals. The majority of virus shedding occurred between days 4 and 6 p.i. (Fig. 2 B) . A comparison of virus shedding among groups showed that animals infected with both gC-negative phenotype viruses shed 10-to 100-fold less virus than those infected with wild-type Cooper virus. This difference in shedding was similar to the growth differences observed in vitro (Fig. 1 C) . A comparison between recombinant gC-negative viruses, gC − \LacZ + and BHV-1\IFNγ, showed no significant differences in virus shedding, indicating that the in vivo expression of recombinant boIFN-γ did not have a significant effect on virus replication. The decreased shedding of the gC-deleted strains also appeared to correlate with smaller plaques in the nasal cavity and earlier resolution of nasal lesions as indicated by the clinical score (data not shown).
During a BHV-1 infection, changes in circulating leukocytes occur within the blood (Griebel et al., 1987) . To study the effects of recombinant BHV-1\IFNγ on blood leukocyte population dynamics, we monitored changes by flow cytometric analysis and by total and differential white blood cell counts. However, there were no significant differences in total and differential blood counts among groups (data not shown). Similarly, FACS analysis of leukocyte subpopulations 3 days p.i. revealed no significant differences in leukocyte sub- 
populations or MHC class II expression on CD4 + T-cells (see Methods).
To determine whether boIFN-γ was secreted in nasal secretions, we collected nasal secretions every second day p.i. and analysed IFN-γ levels by ELISA. As shown in Fig. 3, IFN -γ was detectable in nasal secretions and the level of IFN-γ paralleled virus replication and clinical signs. The level of IFN-γ in nasal secretions peaked on day 4 p.i. for all animals and by day 6 p.i. the level of IFN-γ exceeded 100 pg\ml in nasal secretions of all animals. However, on day 6 p.i. IFN-γ levels in nasal secretions from all the animals in the BHV-1\IFNγ group exceeded 1000 pg\ml, but only a single animal from the other two groups had a similar level of IFN-γ in nasal secretions. A direct comparison between gC − \LacZ + and BHV-1\IFNγ by Student's t-test (P l 0n0567) and the Mann-Whitney ranksum test (P l 0n050) indicated a statistical difference for IFN-γ produced in the nasal cavity. Given that IFN-γ has a half-life of approximately 30 min, we would expect the level of IFN-γ assayed to reflect production during the day of sampling (Kurzrock et al., 1985) . Thus, the elevated level of IFN-γ in BHV-1\IFNγ-infected animals supports the conclusion that C. Raggo and others C. Raggo and others 
BHV-1\IFNγ virus expressed recombinant IFN-γ during infection.
Serum antibody titres for gD were determined by ELISA (van Drunen Littel-van den Hurk et al., 1984) . After the primary intranasal challenge, all animals became sero-positive by week 2 p.i. Peak IgG titres occurred 4 weeks after the primary challenge period (Fig. 4 A) . A secondary rise in serum IgG antibody titres followed dexamethasone reactivation of latent infections and there was no significant difference for total IgG between gC − \LacZ + -and BHV-1\IFNγ-infected animals (Fig.  4 A) . Furthermore, a comparison of the IgG isotypes, IgG1 and IgG2a, revealed no significant differences in the IgG1 : IgG2a ratios of gD-specific antibody induced by the two recombinant viruses (data not shown). Similarly, no statistically significant differences in virus neutralization titres were detectable (data not shown).
Nasal IgA was detected using gD-coated plates and an antibovine IgA MAb (Fig. 4 B) . During the first 5 weeks after primary infection, there were no significant differences in nasal IgA titres for animals infected with the recombinant BHV-1. In contrast, following dexamethasone treatment there was a significant increase in nasal IgA titres in animals infected with wild-type BHV-1 and gC − \LacZ + viruses but not in animals infected with BHV-1\IFNγ (Fig. 4 B) .
To detect virus-specific T-cell responses, peripheral blood lymphocytes were isolated and assayed for gD-specific IFN-γ-secreting cells. The frequency of gD-specific IFN-γ-secreting cells was comparable among all experimental groups, especially the gC − \LacZ + and BHV-1\IFNγ groups (Fig. 5) . The frequency of gD-specific IFN-γ-secreting cells decreased by week 5 after the primary infection but IFN-γ-secreting cell frequency was elevated after reactivation of the latent infection. Similarly, gD-induced proliferative responses of blood lympho- cytes were not significantly different among the three groups after either the primary infection or following reactivation of the latent infection (data not shown).
Reactivation of latent virus
Calves were treated with dexamethasone to determine if recombinant BHV-1\IFNγ established a latent infection and if the IFN-γ gene insert was stable. All animals were clinically normal before dexamethasone treatment but following treatment there was an increase in clinical scores and rectal temperatures that correlated with virus shedding (Fig. 6) . Calves from all three groups shed virus for at least 5 days following treatment and virus shedding peaked 3 days after dexamethasone treatment. As observed during the primary infection, animals infected with wild-type Cooper virus shed 10-to 100-fold more virus than animals infected with recombinant gC-negative viruses. The Cooper group shed a maximum titre of 2n7i10' p.f.u.\ml per swab, while recombinant gC − \LacZ + shed a maximum of 3n6i10% p.f.u.\ml per swab and BHV-1\IFNγ shed a maximum of 2n3i10% p.f.u.\ml per swab. Virus shedding was monitored for 7 days (data not shown), but only one calf from the BHV-1\IFNγ group shed detectable virus (40 p.f.u.\ml). Neither virus titre nor the duration of virus shedding was significantly different between recombinant BHV-1\IFNγ-and gC − \LacZ + -infected animals.
Biologically active IFN-γ was expressed by reactivated virus
To determine whether latent BHV-1\IFNγ retained a functional IFN-γ gene, the virus was re-isolated from nasal swabs of animals treated with dexamethasone. This virus was grown in MDBK cells and the supernatant was analysed for biologically active IFN-γ. As shown in Fig. 7 , supernatant from BHV-1\IFNγ-infected cells up-regulated MHC class II ex-CGHA Recombinant BHV-1 expressing IFN-γ Recombinant BHV-1 expressing IFN-γ pression. Moreover, this activity could be neutralized with anti-IFN-γ antibodies (Fig. 7 F) . The biological activity of recombinant IFN-γ was also confirmed in an anti-virus VSV assay (data not shown). These observations confirmed that latent BHV-1\IFNγ retained a functional boIFN-γ gene.
Discussion
In this report, we established that BHV-1 was a stable vector for cytokine expression. The expression of biologically active IFN-γ was confirmed both in vitro and in vivo during a primary infection and following reactivation of a latent infection. The latent BHV-1\IFNγ recombinant virus retained a functional IFN-γ gene that produced functional IFN-γ protein with both antiviral activity and the ability to up-regulate MHC class II expression (Fig. 7) . These observations confirmed that recombinant BHV-1 is a stable vector. Other virus vectors have not always displayed the same stability. For example, when a recombinant SIV vector expressing IFN-γ was used to infect macaque monkeys, there was a deletion of the IFN-γ gene within 12 weeks p.i. (Giavedoni et al., 1997) . The retrovirus vector tended to be unstable and deleted genetic material when it did not confer an evolutionary advantage (Giavedoni et al., 1997) .
The growth kinetics curve confirmed that recombinant BHV-1\IFNγ was able to replicate in vitro and this replication was comparable to gC − \LacZ + virus (Fig. 1) . This observation suggested that an analysis of the in vivo effects of IFN-γ production would not be complicated by differences in recombinant BHV-1 replication. Therefore, this appeared to be a valid system for evaluating the in vivo expression of recombinant cytokine expression during BHV-1 infection. Nevertheless, deletion of gC, an important glycoprotein for attachment and penetration, resulted in decreased virus replication both in vitro and in vivo (Liang et al., 1991 a, b) .
The primary infection of animals with control virus and recombinant BHV-1\IFNγ showed a similar fever response and clinical signs of infection. The systemic injection of recombinant boIFN-γ can induce a fever response in cattle (Roth & Frank, 1989 ; Chiang et al., 1990) , but there was no indication that production of exogenous IFN-γ by the recombinant BHV-1 vector had significant systemic activity. For example, the level of acute phase protein haptoglobin was similar in the serum of animals from all three groups and there were no significant differences in blood leukocyte populations during primary infection (data not shown). The apparent lack of activity by BHV-1\IFNγ during a primary infection may be explained by the level of endogenous IFN-γ production during an acute BHV-1 infection. All BHV-1-challenged calves produced 2000 pg\ml of IFN-γ in nasal secretions on day 4 p.i. (approximately 6000 U\ml based on 3n0i10' U\mg standard) and produced over 100 pg\ml on day 6 p.i. (Fig. 4) . This indicates that BHV-1 is a potent inducer of IFN-γ production and endogenous IFN-γ production may exceed IFN-γ production by the BHV-1\IFNγ vector. The detection of IFN-γ in nasal secretions correlates with earlier findings of total interferon levels in nasal secretions . In these previous studies, the interferon activity was quantified by inhibition of VSV replication. Therefore, the contribution of each type of interferon to this antiviral activity was not assessed. Traditionally, interferon in nasal secretions has been assumed to be IFN-α (Straub & Ahl, 1976) . The present finding that high levels of IFN-γ are present in nasal secretions following a primary infection suggests that there may be a high number of infiltrating NK cells. The availability of an ELISA for both bovine IFN-α\β and IFN-γ would help quantify the relative contribution of each type of IFN.
In two previous reports, both recombinant VV and SIV displayed reduced virus growth in vivo when expressing recombinant IFN-γ (Kohonen-Corish et al., 1990 ; Giavedoni et al., 1997) . One question that arises from our study is why BHV-1 expressing recombinant IFN-γ did not exhibit an CGHB C. Raggo and others C. Raggo and others attenuated phenotype. One possible explanation may be that unique aspects of VV and SIV life-cycles made this strategy successful. A BHV-1 respiratory infection is limited to primarily nasal, trachea and lung epithelial cells but VV has a wider tropism, infecting cells in various tissues which include ovaries, lungs, spleen and brain (Karupiah et al., 1990 ; Sambhi et al., 1991) . This broader tropism results in a high level of VV replication and subsequently the amount of recombinant cytokine produced may be much greater. For example, infection by certain VV vectors expressing IL-2 and IL-4 can result in clinical symptoms that mimic the administration of large amounts of recombinant cytokine (Bembridge et al., 1998) . Similarly, SIV infects a high number of lymphocytes both in the blood and in the lymph nodes and these infected cells can interact with dendritic cells (Wood, 1990 ; Fauci et al., 1996) . This particular cell tropism would be an asset when expressing recombinant cytokines, since expression could be targeted to the lymph nodes and dendritic cells. This localized expression may increase the potential for immunomodulation by a recombinant cytokine. Furthermore, both VV and SIV may have different sensitivities to the antiviral effects of IFN-γ. For example, transgenic mice without the IFN-γ receptor gene show increased susceptibility to VV infection (Muller et al., 1994) .
The one observation that suggested immunomodulation by recombinant boIFN-γ was a reduced level of IgA in nasal secretions of calves infected with BHV-1\IFNγ after reactivation (Fig. 4 B) . In other animals models, both recombinant VV-IL-2 and VV-IFN-γ induced lower VV-specific antibody responses that correlated with a lower level of virus growth during a primary infection (Kohonen-Corish et al., 1990) . Furthermore, intranasal immunization with a fowlpox virus vector co-expressing influenza virus haemagglutinin and IFN-γ produced no IgA antibody response, yet showed no difference in the CTL responses between recombinant and control (Leong et al., 1994) . Our results with dexamethasone reactivation of BHV-1\IFNγ parallel these findings. However, unlike the fowlpox virus vector, we were able to detect BHV-1-specific IgA in nasal secretions after a primary infection. Since only a fourfold difference in IgA titre was found, further experiments will be necessary to establish if the lack of an anamnestic mucosal IgA response was a direct consequence of recombinant IFN-γ produced by the BHV-1\IFNγ vector.
The observed difference in nasal IgA modulation (Fig. 4 B ) may also be explained by differences in the host environment during a primary infection and reactivation. The primary respiratory infection was initiated with numerous cells being infected and a high level of virus replication until host factors were able to control virus growth. In contrast, reactivation of a latent infection affects a much small number of cells and virus replication occurs within the context of an active host immune response. Thus, production of recombinant IFN-γ may be able to activate virus-specific effector cells and limit virus replication in the reactivated area. However, our analysis of virus shedding in nasal secretions did not indicate that expression of recombinant IFN-γ reduced virus replication following reactivation of the latent infection.
The immunogenicity of gC-negative mutants was previously confirmed by the detection of antibody responses (Liang et al., 1992) , as well as T-cell proliferative responses and NK-like responses (Denis et al., 1996) . Assays for cell-mediated immune responses revealed no differences among the experimental groups for either BHV-1-specific proliferative responses or gD-specific IFN-γ-producing cells (Fig. 5) . These observations indicated that the production of recombinant IFN-γ during a primary infection or recrudescence did not have detectable effects on T-cell responses.
In conclusion, we demonstrated that expression of boIFN-γ by a BHV-1 vector did not cause adverse clinical effects and that the vector expressed cytokine during both a primary and a recrudescent infection. Both gC-negative recombinant viruses (BHV-1\IFNγ and gC − \LacZ + ) induced detectable immune responses but the expression of recombinant IFN-γ did not attenuate virus growth or significantly modulate systemic humoral and cellular immune responses. Analysis of nasal secretions revealed high levels of IFN-γ in calves infected by either wild-type or recombinant BHV-1 and revealed that endogenous IFN-γ production is a natural part of a primary BHV-1 infection. Finally, the expression of recombinant IFN-γ had no detectable effect on virus latency or reactivation of the latent virus. The observed stability of recombinant BHV-1, during a primary and latent infection, suggests that BHV-1 may provide a stable virus vector for the expression of cytokines and possibly other immunomodulating genes. Further studies are required to confirm vector stability following multiple passages within the host. The unique biology of herpesviruses may provide significant advantages for their use as virus vectors.
